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Abstract
The mucosa-associated lymphoid tissue protein-1 (MALT1, also known as paracaspase) is a protease whose activity is
essential for the activation of lymphocytes and the growth of cells derived from human diffuse large B-cell lymphomas of
the activated B-cell subtype (ABC DLBCL). Crystallographic approaches have shown that MALT1 can form dimers via its
protease domain, but why dimerization is relevant for the biological activity of MALT1 remains largely unknown. Using a
molecular modeling approach, we predicted Glu 549 (E549) to be localized within the MALT1 dimer interface and thus
potentially relevant. Experimental mutation of this residue into alanine (E549A) led to a complete impairment of MALT1
proteolytic activity. This correlated with an impaired capacity of the mutant to form dimers of the protease domain in vitro,
and a reduced capacity to promote NF-kB activation and transcription of the growth-promoting cytokine interleukin-2 in
antigen receptor-stimulated lymphocytes. Moreover, this mutant could not rescue the growth of ABC DLBCL cell lines upon
MALT1 silencing. Interestingly, the MALT1 mutant E549A was unable to undergo monoubiquitination, which we identified
previously as a critical step in MALT1 activation. Collectively, these findings suggest a model in which E549 at the
dimerization interface is required for the formation of the enzymatically active, monoubiquitinated form of MALT1.
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Introduction
The protease MALT1 (also known as paracaspase) plays a
central role in the antigen receptor-mediated activation of
lymphocytes and the pathogenesis of human diffuse large B-cell
lymphoma (DLBCL) of the activated B-cell (ABC) subtype [1,2].
In resting naı¨ve lymphocytes, MALT1 is present in its catalytically
inactive form, constitutively associated with the adaptor protein
BCL10 [3,4]. Upon antigen receptor triggering, MALT1 and
BCL10 form a complex with the scaffold protein CARMA1 (also
known as CARD11) [5,6] that promotes the activation of the
transcription factor nuclear factor kappa B (NF-kB). NF-kB drives
the expression of genes that promote the proliferation and survival
of the activated lymphocytes [7]. In resting lymphocytes, NF-kB
complexes are present mainly as p50-RelA and p50-cRel
heterodimers [8]. These are kept inactive by inhibitor of kappa
B (IkB) proteins, which retain NF-kB heterodimers in the
cytoplasm [9], but also by the NF-kB family member RelB, which
acts as an NF-kB inhibitor in lymphocytes by binding RelA and c-
Rel and preventing their DNA binding [10–13]. MALT1
promotes NF-kB activation by both its scaffold and its enzymatic
function [1,2]. As a scaffold, MALT1 promotes the recruitment of
the ubiquitin ligase TRAF6 and the subsequent ubiquitination-
dependent recruitment and activation of the IkB kinase (IKK)
complex, which phosphorylates and thereby initiates the degra-
dation of the NF-kB inhibitor IkBa [14–18]. As an enzyme with
protease activity, MALT1 also promotes NF-kB activation by
cleaving the inhibitor RelB, which is subsequently degraded by the
proteasome [10]. In addition, MALT1 promotes lymphocyte
activation by cleaving A20 and CYLD, deubiquitinating enzymes
that have inhibitory roles in the NF-kB and JNK pathway,
respectively [19,20], and by cleavage of BCL10, which promotes
lymphocyte adhesion [21]. Unlike caspases, MALT1 preferentially
cleaves its substrate after an arginine residue [1,2,22]. Conse-
quently, inhibition of MALT1 with the arginine-based peptide
inhibitor z-VRPR-fmk leads to a significant reduction in antigen-
receptor mediated lymphocyte activation [21].
Recently, the protease activity of MALT1 has received
particular attention as a drug target for the treatment of ABC
DLBCL, a particularly aggressive form of human B-cell lympho-
ma that is dependent on the oncogenic activation of the
CARMA1-BCL10-MALT1 pathway [23–25] and on the protease
activity of MALT1 [26–29]. Indeed, inhibition of the protease
activity of MALT1 with a peptide inhibitor or small molecule
drugs efficiently inhibits the growth of cells derived from ABC
DLBCL in vitro and in xenograft models [26–29]. Constitutive
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MALT1 activity may also be a driving force for the growth of B-
cell lymphomas of the mucosa-associated lymphoid tissue (MALT
lymphomas), which frequently have a chromosomal translocation
that leads to the formation of an oncogenic fusion protein of
MALT1 with the apoptosis inhibitor c-IAP2 [30]. The resulting c-
IAP2-MALT1 fusion protein specifically cleaves the Ser/Thr
kinase NIK and thereby promotes the oncogenic activation of the
alternative NF-kB pathway [31].
Size exclusion chromatography and protein crystallography,
performed in the presence or absence of the irreversible peptide
inhibitor z-VRPR-fmk, show that binding to this substrate analog
promotes the formation of MALT1 dimers that adopt the active
conformation [32,33]. In solution, MALT1 dimerization is favored
by binding to its inhibitor [33]. When crystallized in the absence of
the inhibitor, MALT1 already forms a dimer in which the active
site Cys 464 (C464) adopts an inactive conformation, unable to
form the catalytically active dyad with His 415 (H415) [32]. In this
inactive conformation, the protease domain interacts via hydro-
phobic residues with the adjacent C-terminal immunoglobulin
domain (Ig3). Formation of the active dimeric conformation seems
to be controlled by a conformational change that alters the
interaction of the protease domain with the Ig3 domain [32].
Nevertheless, the exact mechanisms by which the dimerization
and activation of MALT1 are controlled in vivo remain poorly
understood. We recently demonstrated that MALT1 is activated
by monoubiquitination on a Lys residue (K644) that is situated in a
structurally undefined loop within the C-terminal Ig3 domain
[34]. Monoubiquitination of MALT1 is thought to favor or
stabilize the active MALT1 dimer, since C-terminal fusion of a
monoubiquitin moiety to MALT1 generates a constitutively active
form of MALT1 that is preferentially dimeric [34]. These data,
together with the crystallographic data, support the idea that
MALT1 is active as a dimer, but it remains unknown how
dimerization controls the catalytic and biological activity of
MALT1.
Here, we show that a Glu residue (E549) localized within the
dimerization interface of the MALT1 protease domain was critical
for the in vitro dimerization of the MALT1 protease domain.
Mutation of E549 into alanine (E549A) led to complete loss of the
enzymatic activity of MALT1, and to a consequent loss of the
growth-promoting function of MALT1 in lymphocytes and
lymphoma cells. Moreover, the mutant was unable to undergo
monoubiquitination, and its activity could not be restored by
artificial monoubiquitination-induced dimerization. Collectively,
these findings support the idea that E549 within the dimerization
interface of MALT1 plays a critical role in the regulation of the
enzymatic and biological activity of MALT1.
Results
The MALT1 protease domain has sequence similarity with
caspases [4] that have been shown to form catalytically active
dimers [35]. To assess whether MALT1 is able to form dimers, we
initially modeled the three-dimensional structure of the MALT1
protease domain based on the published structures of caspase-9, -3
and -8. The validity of the resulting model of a caspase-like
domain of MALT1 was recently confirmed by published
crystallographic structures of MALT1 [32,33]. Except for the N-
terminal beta strand, all secondary structural elements were
predicted correctly. The Root Mean Square Deviation (RMSD) of
all Ca atoms between our model and the structure of the inhibitor-
bound MALT1 (3UOA.pdb, [33]) is 4.3 A˚ (without N-terminus
and longest loops), while the RMSD of the central beta strands
and the alpha helices in the dimerization interface is below 2 A˚
(Fig. S1), which confirms the general good quality of our
predictions. In the model of the MALT1 dimer, we noticed that
the potential dimerization interface of the MALT1 protease
domain lacked the hydrophobic residues that were previously
described to stabilize the caspase-8 dimer [36]. Instead, by visual
inspection of the model, we noticed the presence of charged
residues, Glu 549 (E549) and Arg 551 (R551), which could
potentially form a salt bridge stabilizing the dimer (Fig. S2). These
residues are invariant across species [33], and we hypothesized
that mutation of these into uncharged alanine residues (E549A
and R551A, respectively) might affect MALT1 dimerization and
activity.
To test this hypothesis, we expressed different MALT1
constructs (Fig. 1A) in HEK293T cells and assessed the
precipitated proteins for their catalytic activity in vitro in the
presence of the kosmotropic salt ammonium citrate, which is
known to activate initiator caspases by favoring their dimerization
[37,38]. As previously reported, wildtype MALT1 was highly
active in ammonium citrate buffer [19,22,34], but this activity was
completely lost in the E549A mutant (Fig. 1B). The R551A
mutant, on the other hand, had only a partial effect on MALT1
activity (Fig. S3), therefore we focused on the E549A mutant for
further analysis. Using a bacterial expression system, we then
generated purified recombinant constructs containing only the
wildtype or E549A mutant MALT1 protease domain (Casp-like
constructs), or the protease domain together with the C-terminal
extension (DNT constructs) (Fig. 1A). Analysis of these constructs
by size exclusion chromatography, under conditions of physiolog-
ical salt concentrations, showed that wildtype MALT1 had some
tendency to spontaneously form dimers in solution, consistent with
previous reports [32,39] (Fig. 1C). Dimerization of the constructs
containing only the protease domain was affected in the E549A
mutant (Fig. 1C), but not in the active site mutant C464A (data
not shown). Impairment of dimerization was no longer apparent
when a construct containing the protease domain and the C-
terminal extension of MALT1 was used (Fig. 1D), suggesting that
the C-terminal region stabilizes the dimer conformation.
Nevertheless, the E549A mutation resulted in the complete loss
of MALT1 catalytic activity towards its substrates BCL10, RelB or
CYLD when co-expressed in HEK293T cells (Fig. 1, E and F).
However, this mutation did not affect the capacity of MALT1 to
bind to BCL10 (Fig. S4). Thus, mutation of E549, which is part of
the dimerization interface, compromises the capacity of the
isolated MALT1 protease domain to form dimers and results in
loss of catalytic activity of full length MALT1 in vitro and in living
cells.
To test the biological relevance of E549-dependent MALT1
activity, we next expressed increasing amounts of wildtype
MALT1, the catalytically inactive mutant C464A or the E549A
mutant together with BCL10 in HEK293T cells, and analyzed the
capacity of these MALT1 constructs to promote NF-kB activation
(Fig. 2A). In HEK293T cells, MALT1 overexpression promotes
NF-kB activation mainly by its scaffold function, and only partially
via its proteolytic activity [21]. Compared to wildtype MALT1,
the mutant E549A had a partially impaired capacity to promote
NF-kB activation in HEK293T cells (Fig. 2A), similar to a
catalytically inactive mutant of MALT1 in which the conserved
cysteine residue C464 of the catalytic site has been mutated into
alanine (MALT1 C464A) [21]. No inhibitory effect on NF-kB
activation, and only a minimal effect on BCL10 cleavage were
observed for the R551A mutant (Fig. 2A). In T cells, the MALT1
protease activity controls the T-cell receptor mediated NF-kB
activation by inducing the cleavage and subsequent degradation of
RelB, which acts as an inhibitor of NF-kB1 in these cells [10–
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Figure 1. Mutation of E549 affects dimerization of the isolated protease domain and the catalytic activity of MALT1. (A) Schematic
representation of the constructs used in this study. (B) The activity of the indicated Strep-tagged MALT1 wildtype (WT) and E549A mutant constructs,
precipitated from transfected HEK293T cells, was determined in vitro in presence of 1 M ammonium citrate using the MALT1 substrate LVSR-amc.
Protein levels in lysates and precipitations were controlled by immunoblot. PD: pull-down. Left margin, molecular size marker in kilodalton (kDa). (C,
D) Recombinant wildtype or E549A-mutant MALT1 proteins corresponding to the isolated protease domain (aa 333–566, MALT1(Casp-like)) (C) or to
the protease domain and the C-terminal extension (aa 333–824, MALT1(DNT)) (D) were analyzed by size exclusion chromatography in presence of
PBS and 10% glycerol, presented as the absorbance at 280 nm (A280) in ‘milli-arbitrary units’ (mAU). Downward arrowheads indicate positions of the
molecular weight standards aldolase (158 kDa), bovine serum albumin (67 kDa) and ovalbumin (43 kDa). (E, F) Strep-tagged MALT1 or its E549A
mutant were co-expressed with VSV-tagged BCL10, FLAG-tagged RelB or FLAG-tagged CYLD in HEK293T cells, as indicated, and protein cleavage was
assessed by immunoblot analysis of lysates. Tubulin served as a loading control throughout. Data are representative of two (B, D, E and F) or three
independent (C) experiments.
doi:10.1371/journal.pone.0072051.g001
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13,40]. We analyzed the effect of the E549A mutant on antigen
receptor-induced activation of the NF-kB pathway in Jurkat T
cells, using a combination of phorbolester (PMA) and ionomycin,
which mimic strong T-cell activation by activation of PKC family
kinases and release of calcium from the ER, respectively. Unlike
the wildtype form of MALT1, the E549A mutant was unable to
promote PMA/ionomycin-induced activation of an NF-kB
reporter gene (Fig. 2B). The activation of T-cells leads to the
NF-kB-dependent production of the growth-promoting cytokine
interleukin-2 (IL-2), which can be monitored at the transcriptional
level using a dual IL-2 luciferase reporter assay. Transduction of
Jurkat T-cells with wildtype MALT1, but not with the E549A
mutant, led to a clear increase in IL-2 gene transcription induced
by stimulation with PMA and ionomycin (Fig. 2C). Similar results
were obtained when the cells were stimulated via the antigen
receptor, using antigen presenting Raji B cells loaded with the
bacterial superantigen staphylococcal enterotoxin E (SEE)
(Fig. 2D). Thus, mutation of E549 within the dimerization
interface of MALT1 renders the MALT1 enzyme biologically
inactive.
MALT1 has been reported to be constitutively active in ABC
DLBCL as a consequence of oncogenic mutations in the B-cell
receptor-associated CD79 chain or the CARMA1 protein
[24,25,41], which act upstream of MALT1 in the signaling
pathway leading from B-cell receptor triggering to NF-kB
activation. The growth and survival of cells derived from ABC
DLBCL is impaired upon silencing of MALT1 expression [23] or
upon treatment of the cells with a MALT1 inhibitor [26,27].
Moreover, impaired cellular survival has been reported for ABC
DLBCL cell lines in which endogenous MALT1 is replaced by
catalytically inactive MALT1 mutants [26,34]. Therefore, we
assessed the effect of the catalytically inactive mutant E549A on
the survival of these cell lines under conditions of silencing of
endogenous MALT1. In contrast to wildtype MALT1, both the
C464A and the E549A mutant were unable to restore the growth
of the ABC DLBCL cell lines, suggesting that E549-dependent
formation of catalytically active MALT1 is essential for its
oncogenic function (Fig. 3).
We have previously reported that MALT1 is modified by
monoubiquitination in activated T cells, and that a construct
mimicking C-terminal monoubiquitination of MALT1 (MALT1-
Ub) is hyperactive, most likely as a consequence of its constitutive
dimerization [34]. In contrast to recombinant unmodified
MALT1, which becomes active upon addition of a kosmotropic
salt in vitro, monoubiquitinated MALT1 is highly active, even in
the absence of kosmotropic salt [34]. However, it has remained
unknown how exactly monoubiquitination affects MALT1 activ-
ity. One possibility is that monoubiquitination is a prerequisite and
thus an initiating trigger for subsequent dimerization. Alternative-
ly, monoubiquitination may be the consequence of a dimerization
that is initially induced via CBM complex formation or substrate
binding. To gain insight into this question, we first assessed
whether the E549A mutant was still able to undergo mono-
ubiquitination. MALT1 monoubiquitination can be induced by
co-expression of MALT1 with BCL10; it is further increased by
the use of a catalytically inactive mutant of MALT1 (C464A) or by
the pretreatment with the MALT1 inhibitor z-VRPR-fmk [34].
When tested under such experimental conditions, the E549A
mutation was unable to undergo monoubiquitination (Fig. 4, A
and B).
Next, we tested the catalytic activity and dimerization capacity
of wildtype and E549A MALT1(DNT) constructs with or without
C-terminally fused ubiquitin. First, we measured the activity of the
corresponding recombinant purified proteins in vitro. The wildtype
form of MALT1(DNT) was active already in PBS (Fig. 4C), and
its activity could be further increased in the presence of 0.5 M
ammonium citrate (Fig. 4D), as previously described [34]. In
contrast, the corresponding E549A mutant showed no detectable
activity, even in the presence of ammonium citrate (Fig. 4, C and
D). C-terminal fusion of a ubiquitin moiety rendered the resulting
wildtype MALT1(DNT)-Ub construct hyperactive, as previously
described [34]. In contrast, C-terminal ubiquitination had only a
minimal impact on the activity of the corresponding E549A-
mutated MALT1(DNT)-Ub construct, which remained extremely
low (Fig. 4, C and D). We also tested the activity of these
constructs using a previously-described MALT1 activity reporter
construct [34]. The construct is composed of enhanced yellow
fluorescent protein (eYFP), followed by enhanced cyan fluorescent
protein (eCFP), with an intervening short linker sequence
containing a cleavage site (Leu-Val-Ser-Arg) previously identified
in the MALT1 substrate RelB [10]. Cleavage of this reporter
construct can be detected by immunoblot using an anti-GFP
antibody that cross-reacts with both eCFP and eYFP. The
wildtype form of the MALT1(DNT)-Ub construct efficiently
cleaved this reporter, but mutation of E549 within the
MALT1(DNT)-Ub construct led to a complete loss of proteolytic
activity (Fig. 4E). However, when analyzed by size exclusion
chromatography, both the wildtype and E549A-mutated forms of
the MALT1(DNT)-Ub construct eluted preferentially as dimers
(Fig. 4F). Collectively, these data suggest that an E549-dependent
conformational change is a prerequisite for MALT1 monoubiqui-
tination, which most likely serves to stabilize the active dimer
conformation (Fig. 5).
Discussion
In the present study, we have provided several lines of evidence
that support a model in which E549 within the dimerization
interface of MALT1 is required to promote the formation of a
monoubiquitinated, catalytically active MALT1 conformation
(Fig. 5). First, we showed that mutation of E549 affected
dimerization of the isolated MALT1 protease domain in vitro,
and inhibited the protease activity of MALT1. Second, we
demonstrated that this mutant is impaired in its capacity to
promote NF-kB activation and the transcription of the NF-kB
target gene IL-2 in activated T cells. Third, we provided evidence
for a role of E549 in promoting the MALT1-dependent growth of
cells derived from ABC DLBCL, which are addicted to this
signaling pathway. Finally, we showed that the E549A mutant was
unable to undergo monoubiquitination, and that artificial C-
terminal monoubiquitination was unable to overcome its activity
defect.
How exactly does E549 affect the catalytic activity of MALT1?
Our initial working hypothesis, based on a modeling approach
predicting similar dimeric structures of the protease domains of
caspases and MALT1, suggested that E549 and R551 are both
located within the conserved b6 strand of the protease domain,
which is the major determinant for the dimerization of caspases
[42]. Our model further suggested that these residues might have a
crucial role in stabilizing the protease-protease interface via
electrostatic interactions. However, unlike the E549A mutant,
the R551A mutant retained considerable enzymatic activity,
arguing against a sole role for these two residues in stabilizing
the protease dimer via an E549-R551 surface interaction. Indeed,
additional interactions between I550 and S552 of opposing b6
strands, and interactions between the a5 and a59 helices of the two
protease subunits of MALT1 are thought to contribute to the
stabilization of its dimeric conformation [33]. Our biochemical
Role of E549 in MALT1 Activation
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Figure 2. The residue E549 is required for the biological activity of MALT1 in T cells. (A) Strep-tagged MALT1 wildtype, its C464A or E549A
mutant were co-expressed with FLAG-tagged BCL10 and an NF-kB reporter construct in HEK293T cells, and NF-kB induction was assessed by dual
luciferase assay. The open and filled arrowheads indicate the positions of endogenous and transfected proteins, respectively. The position of the
cleaved BCL10 (Cl) proteins is indicated. Statistical significance is indicated by stars. *#0.05, **#0.01, ***#0.005 (two-tailed Student’s t-test). (B) Jurkat
cells stably expressing an NF-kB luciferase reporter construct were transfected with indicated Strep-tagged MALT1 constructs, and luciferase reporter
activity was measured upon T-cell stimulation by PMA and ionomycin (PMA+iono) for 16 h. (C) Jurkat cells stably expressing the SV40 large T antigen
(JTag cells) were co-transfected with indicated Strep-tagged MALT1 constructs and an IL-2 reporter plasmid, and luciferase reporter activity was
measured upon T-cell stimulation by PMA and ionomycin (PMA+iono) for 16 h. (D) Jurkat cells were co-transfected with indicated Strep-tagged
MALT1 constructs and an IL-2 reporter plasmid, and luciferase reporter activity was measured upon T-cell stimulation with Raji B cells in the presence
(+) or absence (2) of the superantigen staphylococcus enterotoxin E (SEE) for 16 h. Data are representative of three (A–C) or two (D) independent
experiments.
doi:10.1371/journal.pone.0072051.g002
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data support the idea that E549 contributes to MALT1 activation
not simply by strengthening the dimer surface interactions, but
also by promoting a dimer conformation that can be mono-
ubiquitinated, which dramatically increases MALT1 activity [34].
This idea is compatible with previously published crystallographic
structures of MALT1 that were obtained in the absence and
presence of a peptide inhibitor acting as a substrate analog [32]
(Fig. S5, A and B). In the absence of the MALT1 inhibitor (PDB
code: 3V55 [32]), E549 forms a hydrogen bond with R551 of the
same subunit, but not with R5519 of the opposing subunit (Fig.
S5A). The crystal structures of MALT1 with the bound inhibitor
(PDB code: 3V4O [32] and 3UOA [33]) suggest a major change
in the hydrogen bonds formed by E549, and a crucial role for
E549 in the stabilization of the active conformation of MALT1. In
the substrate bound form, E549 forms a salt bridge with R465 that
affects the position of the active site residue C464 [32], which is
most likely stabilizing the active site conformation (Fig. S5B). The
other changes provoked by substrate binding involve changes in
the conformation of the R551 side chain that allow the formation
of hydrogen bonds between R551 and E549 of opposing MALT1
monomers that further stabilize the dimeric structure [32] (Fig.
S5, B and C). Thus, E549 may control the conformation of the
active form of the dimeric protease domain both by its implication
in a conformational change that renders the catalytic site active,
and by strengthening the interactions between the subunits of the
dimer (Fig. S5C and Fig. 5). Both of these mechanisms are
impaired in our E549A mutant. The R551A mutant had a much
weaker activity defect than the E549A mutant, which can be
explained by R551 being involved in the stabilization of the
conformation of the dimer but not in the formation of the active
site. This hypothesis is consistent with findings of others, which
have reported that an R551V mutant was still able to cleave the
MALT1 substrate BCL10 [32]. In contrast, a R551E mutant
introducing an additional negative charge in the dimerization
interface that might affect the position of E549, had a profound
impact on the activity of MALT1 [32]. The position changes of
the active site residues and the R465, R551 and E549 residues are
part of a cascade of conformational alterations that lead to a
positional rearrangement of the the C-terminal Ig-like domain
[32]. The E549A mutation hinders one of the first steps in this
cascade and might consequently hamper the monoubiquitination
process, for example by affecting the accessibility of the
ubiquitination site K644 [34] or the interaction of the responsible
(unknown) ubiquitin ligase with MALT1.
Figure 3. MALT1 E549 is required for survival of ABC DLBCL cell lines. The indicated ABC DLBCL cell lines were transduced with an inducible
MALT1-specific shRNA and subsequently infected with constructs co-expressing GFP with Strep-MALT1, Strep-MALT1(E549A) or Strep-MALT1(C464A).
Upon doxycycline-induced, shRNA-mediated silencing of endogenous MALT1, the cell viability of double infected GFP+ cells was monitored by flow
cytometry over several days (lower panels). Efficient shRNA-mediated MALT1 silencing (M) was controlled by immunoblot (upper panels). As a
negative control, we used a previously described SC4 shRNA (Co) [52]. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0072051.g003
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Figure 4. MALT1 E549 is required for MALT1 monoubiquitination. (A) Strep-tagged MALT1 wildtype or its E549A mutant were co-expressed
with VSV-tagged BCL10 in HEK293T cells, and monoubiquitination of immunoprecipitated MALT1 was assessed by immunoblot. The asterisk (*)
indicates monoubiquitinated MALT1. (B) Strep-tagged MALT1 wildtype or its E549A mutant were expressed in HEK293T cells, treated overnight with
(+) or without (2) 100 mM of the MALT1 inhibitor z-VRPR-fmk, and MALT1 monoubiquitination was assessed by immunoblot. (C, D) The protease
activity of the indicated recombinant purified proteins was determined using the fluorogenic MALT1 substrate LVSR-amc in vitro in PBS (C) or in the
Role of E549 in MALT1 Activation
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e72051
How does monoubiquitination affect the activation of MALT1?
We have previously shown that addition of a C-terminal
monoubiquitin moiety to MALT1 favors dimerization and
activation of wildtype MALT1 [34]. In the case of the E549A
mutant, such an artificial monoubiquitination did induce dimer-
ization, but was not sufficient for MALT1 activation. Therefore,
we propose a three-step model of MALT1 activation (Fig. 5),
which includes as a first step an initial low affinity dimerization of
MALT1 through induced proximity, as part of the CBM complex
formation [43], and as a second step an E549-dependent
conformational switch upon substrate binding, to allow formation
of active dimers. Most likely, these active dimers need to be
stabilized in a third step by monoubiquitination. In agreement
with such a model, we observed that the E549A mutant was no
longer monoubiquitinated, and that artificial C-terminal mono-
ubiquitination of this mutant forced its dimerization, but was
unable to overcome its activity defect. Thus, an E549-dependent
conformational switch seems to be required for the subsequent
stabilization of catalytically active MALT1 dimers by monoubi-
quitination (Fig. 5).
The data presented here and in our previous study [34] identify
a unique mechanism of MALT1 activation that is clearly distinct
from the activation of caspases, in which autoprocessing of the L2
and L29 loops of the protease domains serves as a key event to
stabilize the active conformation [4,19,21,22]. Moreover, our
findings support the idea that small molecule compounds
specifically targeting the MALT1 dimerization interface could be
useful as immunosuppressant or anti-lymphoma agents.
Materials and Methods
Modeling
Suitable templates for constructing a homology model of the
caspase-like domain of MALT1 were identified using the HHpred
method [44]. The model of the monomeric MALT1 protease
domain was calculated based on the crystal structures of caspase-9,
-3 and -8 (PDB codes 1NW9, 1CP3 and 2C2Z) sharing 19%, 18%
and 18% sequence identity, respectively, with the MALT1
caspase-like domain. The dimeric MALT1 structure was calcu-
lated using the structure of caspase-8 (1F9E) as a template.
Analogically to the mature/active structures of caspases the
structure of MALT1 was modeled as cleaved after the R467
residue. The alignment (Fig. S6) and the modeling were done
using the Modeller 9v5 program [45] and subsequent model
energy minimization (200 steps of steepest descent minimization in
vacuo) with the CHARMM package (version c34b) using the
CHARMM22 all atom force field [46]. The Atomic Non-Local
Environment Assessment (ANOLEA) potential [47] was employed
to assess the quality of each of the structures and the conformation
with the best overall score was chosen. The models were visualized
using the UCSF Chimera software [48].
presence of 0.5 M ammonium citrate (D). Statistical significance is indicated by stars. *#0.05, **#0.01, ***#0.005 (two-tailed Student’s t-test). (E)
Indicated Strep-tagged MALT1 wildtype or E549A constructs were co-expressed with the reporter construct eYFP-LVSR-eCFP in HEK293T cells, and
reporter cleavage was assessed by anti-GFP immunoblot (which detects both eCFP and eYFP). (F) Recombinant wildtype or E549A-mutant MALT1-Ub
fusion proteins corresponding to the protease domain and C-terminal extension (aa 333–824, MALT1(DNT)-Ub) were analyzed by size exclusion
chromatography in presence of PBS and 10% glycerol, and presented as the absorbance at 280 nm (A280) in milliarbitrary units’ (mAU). Downward
arrowheads indicate the positions of the molecular weight standards ovalbumin (43 kDa) and bovine serum albumin (67 kDa). Data are
representative of two (A, C, D and F) or three (B and E) independent experiments.
doi:10.1371/journal.pone.0072051.g004
Figure 5. Hypothetical model of MALT1 activation. Upon antigen receptor activation, MALT1 may dimerize initially by an induced proximity
mechanism that could be driven by assembly of the oligomeric CARMA1-BCL10-MALT1 (CBM) complex [43]. Upon substrate binding, E549
(highlighted in bold) in the dimerization interface most likely transmits a conformational change that strengthens dimerization. In this conformation,
the active site C464 is reoriented via interaction of R465 with E549, and residues I550 and S552 of opposite subunits interact at the dimerization
interface, as suggested by previous crystallographic studies [32,33]. Our data support the idea that only the dimer in which the two subunits are
correctly assembled in this E549-dependent manner can then be stabilized by monoubiquitination. Additional interactions between the a5 and a59
helices of the two protease subunits that are thought to further stabilize the dimer interaction [33] are not shown in the model.
doi:10.1371/journal.pone.0072051.g005
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Antibodies
Antibody against BCL10 (H197) was purchased from Santa
Cruz Biotechnology, anti-Tubulin (B-5-1-2), anti-RelB (rabbit
polyclonal) and anti-CYLD (D1A10) from Cell Signaling. Anti-
FLAG (M2) and rabbit anti-VSV were from Sigma. Other
antibodies used were anti-Strep-HRP (IBA BioTAGnology), anti-
GFP (ALX 210-199; Enzo LifeSciences) and anti-Ubiquitin
(P4D1; Covance). Affinity-purified MALT1 antibodies and anti-
bodies specific for cleaved BCL10 have been previously reported
[21,49]. Horseradish peroxidase–coupled goat anti-mouse or anti-
rabbit were from Jackson Immunoresearch.
Plasmids
MALT1 point mutants were generated on pCR3-derived
MALT1 expression constructs [21] by quick-change PCR using
PfuUltra high-fidelity DNA polymerase AD (Agilent Technologies)
and all mutations were verified by sequencing. The EYFP-LVSR-
ECFP reporter construct, as well as the eukaryotic (pCR3-based)
and bacterial (pGEX-based) MALT1-Ubiquitin constructs have
been previously reported [34]. For silencing of MALT1 in DLBCL
cell lines, cells were transduced with MALT1-specific shRNA (59-
GTCACAGAATTGAGTGATTTC-39) as published [23].
MALT1 expression constructs resistant to shRNA-mediated
silencing were subcloned into pMSCV-IRES-GFP [50]. The
eYFP–Leu-Val-Ser-Arg–eCFP construct used to measure MALT1
activity and the lentiviral NF-kB reporter construct were
generated as described [34].
Transfection of Cells
Transient transfection of HEK293T cells and lentiviral trans-
duction of Jurkat T cells have been previously described [21]. To
transiently transfect Jurkat T cells by electroporation, 107 cells
were resuspended in 350 ml DPBS (Gibco) supplemented with
CaCl2 and MgCl2 (100 mg/L each), and electroporated at 240 V,
950 mF using the GenePulser Xcell (Biorad) and 4 mm cuvettes
(BTX).
Cell Culture, Cell Stimulation and NF-kB Reporter Assays
HEK293T, Jurkat T cells and JTag cells were cultured in
DMEM or in RPMI 1640 supplemented with 10% FCS and
antibiotics, respectively. Lentivirally transduced Jurkat T cells were
kept under puromycin selection (5 mg/ml) at all times. The ABC
DLBCL cell lines HBL-1, OCI-Ly3 and OCI-Ly10 were cultured
as described [26]. T cells were stimulated with either a mix of
PMA (10 ng/ml; Alexis) and ionomycin (1 mM; Calbiochem) or
with Raji cells presenting the superantigen SEE (streptococcal
enterotoxin E; final concentration: 50 ng/ml). HEK293T cells
were incubated with z-VRPR-fmk (100 mM) for 22 h. NF-kB or
IL-2 dual luciferase reporter assays were performed as previously
described [10].
Lysis, Protein Precipitation and Immunoblotting
Cells were lysed in lysis buffer containing 50 mM HEPES
pH 7.5, 150 mM NaCl, 1% Triton-X-100, protease inhibitors
(Complete; Roche) and phosphatase inhibitors (NaF, Na4P2O7
and Na3VO4). After preclearing the lysates with sepharose beads
for 20 min, StrepTactin sepharose beads (IBA) were added and
samples were incubated for 30 min at 4uC. The samples were then
washed three times with lysis buffer and once with Tris-NaCl
buffer (20 mM Tris pH 7.4, 150 mM NaCl). Where indicated,
some samples were lysed with 1% SDS. After quenching the
samples in a 1:10 ratio with lysis buffer, Strep-MALT1 was
recovered by precipitation with anti-MALT1 antibody coupled to
protein G sepharose. Samples were boiled in reducing SDS sample
buffer and subjected to SDS-PAGE and immunoblot as described
[21].
Protein Purification and Analysis by FPLC
Recombinant GST proteins containing the MALT1 caspase-
like domain only, the caspase-like domain and the C-terminus
(MALT1(DNT)), or the same construct fused to ubiquitin Ub
(MALT1(DNT)-Ub), mutated or not at E549, were generated and
purified as previously described [21]. For gel filtration analysis,
IPTG-induced BL21 bacteria were lysed in a buffer containing
50 mM HEPES, pH 7.9, 300 mM NaCl, 1 mM EDTA, 0.1%
NP-40, 2 mM DTT, protease inhibitors (Complete; Roche) and
5% glycerol. After lysis, glycerol concentration was increased to
10% and GST proteins were immobilized for 2.5 h at 4uC on
glutathione-Sepharose beads (GE Healthcare). After extensive
washing, beads were incubated for 2.5 h at 4uC with PreScission
enzyme (GE Healthcare) in wash buffer containing 5% glycerol.
Purified proteins were subjected to gel filtration performed on an
A¨KTA FPLC system at 4uC using a Superdex 200 column (GE
Healthcare) in PBS with 10% glycerol (pH 7.4) with a flow rate of
0.35 ml/min.
In vitro Protease Activity Assay
To measure protease activity in vitro, recombinant or precipi-
tated proteins were incubated with 50 mM of the fluorescent
substrate Ac-LVSR-amc (Peptides International) for 4 h at 30uC,
while detecting the protease activity of MALT1 with a Synergy
microplate reader (BioTek).
Retroviral Transduction and MALT1 shRNA Rescue
For efficient retroviral transductions, cell lines were engineered
to express the murine ecotropic receptor as previously described
[23]. Additionally, these cell lines were engineered to express the
bacterial tetracycline repressor allowing doxycycline-inducible
shRNA expression [23]. For shRNA induction, doxycycline
(20 ng/ml) was used [23,51]. For the MALT1 rescue experiment,
cells were stably transduced with the MALT1 shRNA. The
MALT1 shRNA-positive cells were subsequently transduced to
constitutively express GFP together with Strep-MALT1 wildtype,
Strep-MALT1(E549A), or Strep-MALT1(C464A). In order to
induce knockdown of the endogenous MALT1 and not the
exogenously expressed Strep-MALT1 variants, the shRNA
binding sites in these constructs were mutated at cDNA position
313 from GAATTG to GAGTTA, without changing the encoded
amino acids. The double-transduced cells were monitored for live
GFP+ cells using flow cytometry as previously described [10].
Statistical Analysis
Two-tailed Student’s t-test was used for statistical analysis; P
values #0.05 were considered statistically significant.
Supporting Information
Figure S1 Comparison of the modeled and crystallo-
graphic structure of the MALT1 caspase-like domain.
Superposition of the homology model and the inhibitor bound
crystal structure of MALT1 (3UOA.pdb) [33] with the color-
coded RMSD values calculated over Ca atoms. The colors used
indicate different RMSD values; red: over 4 A˚, blue: 2–4 A˚, green:
below 2 A˚. The crystal structure is shown in transparent white.
(TIF)
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Figure S2 The dimerization interface in the homology
model of MALT1. Model of the MALT1 protease domain,
calculated based on the crystal structures of caspase-9, -3 and -8
(PDB codes 1NW9, 1CP3 and 2C2Z, respectively) and the dimeric
structure of caspase-8 (1F9E). One of the dimer subunits is shown
in beige, the other one in green. Side chains of residues C464,
R465, E549 and R551 are shown in ball and stick representation,
with nitrogen atoms in blue and oxygen atoms in red. Predicted
hydrogen bonds between E549 and R551, and between R465 and
E549, are indicated (dashed lines). The figure was prepared using
Chimera software [48].
(TIF)
Figure S3 Mutation of Arg551 into Ala partially impairs
MALT1 catalytic activity in vitro. The activity of the
indicated Strep-tagged MALT1 wildtype (WT) and R551A
mutant construct, precipitated from transfected HEK293T cells,
was determined in vitro in presence of 1 M ammonium citrate
using the MALT1 substrate LVSR-amc. Protein levels in lysates
and precipitations were controlled by immunoblot. Left margin,
molecular size marker in kilodalton (kDa). Black lines indicate
where lanes have been removed. PD: pull-down.
(TIF)
Figure S4 Mutation of Glu549 into Ala does not affect
binding of MALT1 to BCL10. To assess whether mutation of
Glu549 into alanine (E549A) affects the binding of MALT1 to
BCL10, HEK293T cells were transfected with the indicated
combinations of Flag-tagged BCL10 and Strep-tagged MALT1
wildtype, or E549A expression constructs, and StrepTactin
precipitates and cell lysates were blotted with the indicated
antibodies. PD: pull-down.
(TIF)
Figure S5 The dimerization interface in the crystal
structures of the free and inhibitor-bound forms of
MALT1. (A) Crystal structure of the dimeric MALT1 protease
domain in the absence of the MALT1 inhibitor (PDB code: 3V55)
[32]. Zoom shows dimerization interface and the position of the
catalytic site cysteine residue of one subunit. Side chains of
residues C464, R465, E549 and R551 are shown in ball and stick
representation, with nitrogen atoms in blue and oxygen atoms in
red. Hydrogen bonds between side chains of E549 and R551
residues are represented with dashed lines. The figures were
prepared with Chimera software [48]. (B) Crystal structure of the
dimeric MALT1 protease domain in the presence of the MALT1
inhibitor z-VRPR-fmk (PDB code: 3V4O) [32]. The inhibitor is
shown in dark green. Zoom shows dimerization interface and the
position of the catalytic site cysteine residue of one subunit.
Residues C464, R465, E549 and R551 are shown in ball and stick
representation, with nitrogen atoms in blue and oxygen atoms in
red. The hydrogen bonds between the side chains of E549 and
R551 and between R465 and E549 are indicated with dashed
lines. The figures were prepared with Chimera software [48]. (C)
Superposition of the dimerization interfaces shown in (A) and (B).
Black arrows indicate movements of the side chains in response to
inhibitor binding.
(TIF)
Figure S6 Alignment of the protease sequences used for
modeling. Alignment of the MALT1 caspase-like domain and
caspase-3, -8, -9 sequences used for building the MALT1
homology model. The coloring scheme used for conserved
residues in the alignment is indicated; green: polar amino acids,
blue: hydrophobic amino acids, red: basic amino acids, magenta:
acidic amino acids, cyan: aromatic amino acids, orange: Gly
residues, yellow: Pro residues, pink: Cys residues. Alignment was
visualized with Jalview [53].
(TIF)
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